EULAR Rheumatoid Arthritis Management Recommendations 2025 Update

What are the EULAR Rheumatoid Arthritis Management Recommendations 2025 Update?

The EULAR Rheumatoid Arthritis Management Recommendations 2025 Update provides evidence-based guidance on the use of conventional, biologic, and targeted synthetic DMARDs in rheumatoid arthritis. It is designed for rheumatologists, trainees, healthcare professionals, researchers, and patients seeking current best practices in RA treatment.

Introduction

The EULAR Rheumatoid Arthritis Management Recommendations 2025 Update represents one of the most important contemporary guidance documents in rheumatology.

Developed by an international task force of experts, the recommendations provide updated evidence-based strategies for managing rheumatoid arthritis (RA) using conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs).

Rheumatoid arthritis remains a chronic inflammatory autoimmune disease associated with progressive joint damage, disability, reduced quality of life, and significant healthcare costs.

Over the past several decades, advances in immunology and targeted therapies have transformed patient outcomes. However, clinicians continue to face important questions regarding treatment sequencing, safety considerations, treatment targets, and long-term disease management.

The 2025 EULAR update addresses these issues by incorporating the latest evidence regarding efficacy, safety, treat-to-target strategies, biologic therapies, Janus kinase (JAK) inhibitors, glucocorticoids, and treatment tapering.

This document is particularly valuable for rheumatologists, internal medicine physicians, residents, fellows, healthcare professionals involved in RA care, and researchers seeking an authoritative summary of current best practices.

Guideline Overview

Full Title

EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biologic Disease-Modifying Antirheumatic Drugs: 2025 Update

Lead Authors

Josef S. Smolen, Christopher J. Edwards, Victoria Konzett, Faidra Laskou, Daniel Aletaha, and an international EULAR task force

Journal

Annals of the Rheumatic Diseases

Publication Year

2026

DOI

10.1016/j.ard.2026.01.023

Medical Specialty

Rheumatology

Intended Audience

• Rheumatologists
• Internal medicine physicians
• Rheumatology fellows
• Medical residents
• Healthcare professionals involved in rheumatic disease management
• Researchers
• Patients interested in evidence-based RA treatment

What This Guideline Covers

The EULAR 2025 update provides a comprehensive framework for modern rheumatoid arthritis management.

Major topics addressed include:

Early Diagnosis and Treatment

The guideline emphasizes that DMARD therapy should be initiated as soon as rheumatoid arthritis is diagnosed. Early intervention remains a cornerstone of successful disease control and long-term outcome improvement.

Treat-to-Target Strategy

A central concept throughout the recommendations is the treat-to-target approach.

The preferred target is:

• Sustained remission whenever achievable
• Low disease activity when remission cannot be attained

The recommendations reinforce the importance of regular disease activity monitoring and timely treatment adjustments.

Conventional Synthetic DMARDs

The document continues to support methotrexate (MTX) as the preferred first-line therapy for most patients.

Alternative options when MTX cannot be used include:

• Leflunomide
• Sulfasalazine

Glucocorticoid Use

Short-term glucocorticoid therapy remains an accepted bridging strategy when initiating or modifying conventional DMARD treatment.

However, glucocorticoids should be tapered and discontinued as rapidly as clinically feasible.

Biologic DMARDs

The guideline discusses biologic therapies, including:

• TNF inhibitors
• Abatacept
• Rituximab
• Tocilizumab
• Sarilumab
• Biosimilar agents

JAK Inhibitors

The recommendations evaluate:

• Tofacitinib
• Baricitinib
• Filgotinib
• Upadacitinib

Special attention is given to safety concerns, including:

• Major cardiovascular events
• Malignancy risk
• Thromboembolic complications

Treatment Sequencing

The update provides guidance on therapeutic escalation when treatment goals are not achieved and offers recommendations regarding switching between biologic and targeted therapies.

Tapering Strategies

Patients who achieve sustained remission may be candidates for cautious dose reduction. Complete discontinuation of therapy is generally discouraged because disease flares frequently occur after treatment withdrawal.

Key Features

• Evidence-based recommendations developed by an international expert task force
• Updated review of biologic and targeted synthetic DMARDs
• Comprehensive discussion of JAK inhibitor safety
• Strong emphasis on treat-to-target principles
• Practical guidance on treatment escalation
• Recommendations regarding remission maintenance
• Consideration of patient-centered care and shared decision-making.
• Integration of efficacy, safety, and economic considerations
• Global relevance across healthcare systems
• Research agenda highlighting future priorities.

Who Should Read This Guideline

Rheumatologists

This document serves as a practical framework for evidence-based treatment decisions in daily clinical practice.

Internal Medicine Physicians

Clinicians managing patients with autoimmune diseases will benefit from understanding current RA treatment standards.

Residents and Fellows

The guideline provides an excellent overview of contemporary RA management strategies and therapeutic sequencing.

Medical Students

Students interested in rheumatology can gain insight into modern evidence-based treatment approaches.

Nurses and Allied Health Professionals

Healthcare professionals involved in RA management can better understand treatment goals and monitoring strategies.

Researchers

The publication identifies knowledge gaps and future research priorities in rheumatoid arthritis.

Examination Candidates

Candidates preparing for rheumatology board examinations may find the recommendations particularly useful because they summarize current therapeutic standards.

Why This Guideline Is Useful

Clinical Relevance

The recommendations directly address real-world treatment decisions encountered in routine rheumatology practice.

Evidence-Based Approach

All recommendations are supported by systematic literature reviews and structured expert consensus processes.

Practical Application

The guideline provides actionable recommendations regarding:

• Initial treatment
• Treatment escalation
• Monitoring
• Remission management

Safety Guidance

The document offers a detailed discussion regarding medication-related risks and monitoring considerations.

Patient-Centered Care

Shared decision-making remains a fundamental principle throughout the recommendations.

Recommendations Overview

The guideline contains five overarching principles and nine major treatment recommendations.

Overarching Principles

1. Shared decision-making between the patient and the rheumatologist.
2. Treatment decisions based on disease activity and safety considerations.
3. Rheumatologists are primary specialists in RA management.
4. Need for access to multiple therapeutic options.
5. Consideration of individual and societal healthcare costs.

Core Treatment Recommendations

1. Start DMARD therapy promptly after diagnosis.
2. Target sustained remission or low disease activity.
3. Monitor disease activity regularly.
4. Use methotrexate as part of the initial treatment strategy.
5. Consider short-term glucocorticoids.
6. Add biologic DMARDs when conventional therapy fails.
7. Combine biologics with conventional DMARDs when possible.
8. Switch therapies appropriately after treatment failure.
9. Consider dose reduction only after sustained remission.

Get: EULAR Rheumatoid Arthritis Management Recommendations 2025 Update